The CCDC93 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population for loss-of-function studies of CCDC93. Generated by transient Cas9/gRNA expression in A-549 cells, the polyclonal pool contains diverse gene disruptions, avoiding clonal bias. This format enables robust, acute knockout experiments without monoclonal isolation, facilitating high-throughput screening and functional assays in endosomal recycling research.
The parental A-549 cell line is a human lung adenocarcinoma epithelial model derived from a 58-year-old male. These cells exhibit alveolar type II features and are extensively used in cancer biology, drug response, and respiratory signaling studies. Their epithelial morphology and genetic stability provide a relevant context for investigating receptor trafficking pathways in NSCLC, making them an ideal host for CCDC93 knockout.
CCDC93 is a critical component of the CCC endosomal sorting complex, which orchestrates recycling of internalized receptors to the plasma membrane. It forms a stable interaction with CCDC22 and COMMD proteins, linking the WASH and retromer complexes to endosomes. Knockout disrupts retrieval of Notch and TGF-beta receptors, causing reduced surface expression and attenuated downstream signaling. Notably, decreased Notch1 leads to lower transcription of targets like HES1, while impaired TGFBR1 recycling blunts TGF-beta-induced gene responses. Thus, CCDC93 loss selectively attenuates signaling from these receptors by diverting them toward lysosomal degradation.
In A-549 cells, CCDC93 knockout perturbs endocytic trafficking critical for oncogenic signaling. Aberrant Notch and TGF-beta pathways are implicated in lung adenocarcinoma progression, EMT, and metastasis. This model enables dissection of how receptor recycling defects alter cancer cell behavior, including proliferation, migration, and drug sensitivity. The polyclonal population mirrors tumor heterogeneity, enhancing translational relevance for target validation and pathway dissection in a disease-relevant background.
Researchers can employ this model in immunofluorescence-based tracking of endosomal markers, flow cytometry for surface receptor quantification, Western blotting for CCDC93 and interacting partners, and Notch reporter assays. Applications span cancer cell biology, neurodevelopmental disease modeling, and receptor recycling mechanistic studies. Co-immunoprecipitation experiments can verify complex formation with CCDC22 and COMMD1. The polyclonal knockout also supports small-molecule screens targeting endosomal trafficking. For technical inquiries, please contact Ascent Research.
